🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Health Concern

Cases of gonorrhoea are on the rise around the world, with estimates suggesting more than 82 million new cases each year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Health officials are deeply concerned about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Authorization

Zoliflodacin, also known as a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Global Access

Based on findings detailed in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The trial included over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared hope. Access to a one-pill regimen such as this is described as a "game-changer" for managing the epidemic. This is considered essential to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.